News Column

DGAP-Adhoc: Biotest AG: Biotest increases earnings after taxes by 38.5%

February 20, 2014

Biotest AG / Key word(s): Preliminary Results 20.02.2014 10:30 Dissemination of an Ad hoc announcement according to 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad-hoc RELEASE Announcement according to 15 Sec. 1 Securities Trading Act (WpHG) Biotest increases earnings after taxes by 38.5% Dreieich, 20. February 2014. According to preliminary and unaudited figures, the Biotest Group recorded earnings after tax (EAT) of EUR 32.0 million, an increase from EUR 23.1 million in 2012 by 38.5%. Earnings before taxes (EBT) increased by 31.0% to EUR 47.8 million (previous year result EUR 36.5 million). The main factors for this profit increase were significant higher sales in the US and in Asia. The Group's earnings before interest and tax (EBIT) have increased disproportionately to sales by 20.4%. to EUR 53.8 million compared to the previous year's EBIT of EUR 44.7 million. As a result the EBIT margin increased from 10.2% to 10.7%. In the financial year 2013 Biotest reached sales of EUR 500.8 million, an increase of 13.8% compared to the previous year (EUR 440.0 million). Biotest will publish final results for the Financial Year 2013 and the annual report on March 25th, 2014. The Annual General Meeting of Biotest AG will take place on May 7th, 2014 in Frankfurt a.M. Biotest Aktiengesellschaft The Executive Management Board Biotest AG Landsteinerstr. 5 D-63303 Dreieich Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has about 1.800 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange. Securities' ID No., ISIN ordinary shares: 522720, DE0005227201 Securities' ID No., ISIN preference shares: 522723, DE0005227235 Listing: Prime Standard Open market: Berlin-Bremen, DÜsseldorf, Frankfurt, Hamburg, Hannover, MÜnchen, Stuttgart20.02.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at and --------------------------------------------------------------------------- Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: Internet: ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Indices: SDAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, DÜsseldorf, Hamburg, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: DGAP Ad Hoc Disclosures

Story Tools